JP-2266
/ Jeil
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 01, 2024
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
(clinicaltrials.gov)
- P2 | N=156 | Not yet recruiting | Sponsor: Jeil Pharmaceutical Co., Ltd.
Trial completion date • Trial initiation date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1